Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Patterson Companies (PDCO) Beats On Q1 Earnings, Keeps View

Published 08/23/2017, 09:06 PM
Updated 07/09/2023, 06:31 AM

Patterson Companies Inc. (NASDAQ:PDCO) reported first-quarter fiscal 2018 adjusted earnings of 44 cents per share from continuing operations, which outpaced the Zacks Consensus Estimate of 43 cents. The figure, however, came lower than the year-ago quarterly figure of 51 cents.

Net sales from continuing operations dipped 2.1% from the year-ago quarter to $1.30 billion missing the Zacks Consensus Estimate of $1.34 billion.

Quarter Details

Coming to the Animal Health platform (60% of total sales), sales increased almost 1.8% on a year-over-year basis to $776.1 million. Sales of Consumable grew 2.2% year over year. However, other services and products on this platform witnessed a 23.4% year-over-year decline in sales.

Patterson Companies’ Dental platform (40% of total sales) sales declined 6.5% year over year to $518.8 million approximately. Consumable sales at the Dental platform dropped 3.8% year over year to $320.2 million, while sales from other services and products decreased 0.6%. Sales from dental equipment and software dipped 15.3%.

Patterson Companies, Inc. Price, Consensus and EPS Surprise

Patterson Companies, Inc. Price, Consensus and EPS Surprise | Patterson Companies, Inc. Quote

Financial Condition

Cash and cash equivalents were $99.8 million as of Jul 29, 2017 compared with $95.0 million as of Apr 29, 2017. In the reported quarter, Patterson repurchased approximately 0.8 million shares for $37.5 million. The company also disbursed $25.2 million in cash dividends to shareholders in the first quarter.

Outlook

Patterson Companies affirmed its adjusted earnings in the range of $2.25-$2.40 per share for fiscal 2018. GAAP earnings are expected to be in the range of $1.90 to $2.05 per diluted share.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks Rank & Key Picks

Patterson Companies currently has a Zacks Rank #4 (Sell).

A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corp. (NYSE:EW) , IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Cogentix Medical, Inc. (NASDAQ:CGNT) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories and Cogentix Medical carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Edwards Lifesciences delivered an average earnings beat of 10.8% over the trailing four quarters.

Cogentix Medical delivered a positive earnings surprise of 200% in the last reported quarter.

IDEXX Laboratories delivered an average earnings beat of 9.3% over the trailing four quarters.

One Simple Trading Idea

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.

Learn more >>



IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

Cogentix Medical, Inc. (CGNT): Free Stock Analysis Report

Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

Patterson Companies, Inc. (PDCO): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.